Valuation: AbCellera Biologics Inc.

Market Cap 4.51B 3.97B 3.75B 3.4B 6.39B 433B 6.43B 44.92B 17.35B 221B 16.94B 16.57B 710B P/E 2026 *
-21.1x
P/E 2027 * -18.6x
Enterprise Value 4.22B 3.71B 3.51B 3.18B 5.98B 405B 6.01B 42.02B 16.23B 207B 15.84B 15.5B 664B EV / Sales 2026 *
155x
EV / Sales 2027 * 141x
Free-Float
78.26%
Yield 2026 *
-
Yield 2027 * -
1 day+9.61%
1 week+10.21%
Current month+21.25%
1 month+12.26%
3 months+88.62%
6 months+325.69%
Current year+307.02%
1 week 11.78
Extreme 11.78
14.23
1 month 10.32
Extreme 10.32
14.23
Current year 2.74
Extreme 2.745
14.23
1 year 2.74
Extreme 2.745
14.23
3 years 1.89
Extreme 1.8906
14.23
5 years 1.89
Extreme 1.8906
20.3
10 years 1.89
Extreme 1.8906
71.91
Manager TitleAgeSince
Chief Executive Officer 51 2012-11-07
Chief Operating Officer 41 2012-11-07
Director of Finance/CFO 52 2019-07-31
Director TitleAgeSince
Chairman 51 2012-11-07
Director/Board Member 41 2012-11-07
Director/Board Member 74 2019-09-30
Date Insider Type Main position Quantity % Market Cap. Importance
8/24/26 Buy

Director

53,613 0.0176%
8/18/26 Buy

Director

10,000 0.0033%
8/14/26 Buy

Chief Financial Officer

37,200 0.0122%
Change 5-day change 1-year change 3-year change Capi.($)
+9.61%+10.21%+193.67%+195.54% 4.12B
+2.64%+7.07%+11.87%+38.40% 47.97B
+0.22%+1.71%+50.91%+34.00% 44.5B
-1.58%+5.65%+359.34%+598.06% 43.93B
+1.70%+4.61%+12.56%+90.97% 41.03B
+0.51%-0.61%+5.18%+46.87% 29.85B
-0.48%+0.59%+23.98%+148.36% 17.27B
+0.08%+9.30%+8.41% - 15.34B
+1.76%+2.98%+29.13%+45.78% 15.3B
+1.97%-2.82% - - 14.82B
Average +1.60%+2.27%+77.23%+149.75% 27.41B
Weighted average by Cap. +0.85%+2.94%+81.28%+159.15%

Financials

2026 *2027 *
Net sales 27.29M 24M 22.69M 20.58M 38.66M 2.62B 38.88M 272M 105M 1.34B 102M 100M 4.3B 30.75M 27.04M 25.57M 23.19M 43.56M 2.95B 43.81M 306M 118M 1.51B 115M 113M 4.84B
Net income -204M -179M -170M -154M -289M -19.59B -291M -2.03B -785M -10B -766M -750M -32.12B -242M -213M -201M -182M -343M -23.21B -345M -2.41B -930M -11.84B -908M -888M -38.06B
Net Debt -291M -256M -242M -219M -412M -27.9B -414M -2.89B -1.12B -14.23B -1.09B -1.07B -45.74B -188M -165M -156M -142M -266M -18.03B -268M -1.87B -722M -9.2B -705M -690M -29.56B
Logo AbCellera Biologics Inc.
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.
Employees
562
Date Price Change Volume
26-09-28 US$13.92 +9.61% 7,759,483
26-09-25 US$12.70 +0.40% 3,383,870
26-09-24 US$12.65 +2.76% 4,990,522
26-09-23 US$12.31 -2.69% 3,854,932
26-09-22 US$12.65 -0.08% 4,285,265
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
13.92USD
Average target price
16.67USD
Spread / Average Target
+19.73%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABCL Stock